- Home
- GNFT vs TVGN Comparison
GNFT vs TVGN Comparison
Compare GNFT & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNFT
- TVGN
- Stock Information
- Founded
- GNFT 1999
- TVGN 2020
- Country
- GNFT France
- TVGN United States
- Employees
- GNFT N/A
- TVGN N/A
- Industry
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- TVGN Blank Checks
- Sector
- GNFT Health Care
- TVGN Finance
- Exchange
- GNFT Nasdaq
- TVGN Nasdaq
- Market Cap
- GNFT 214.5M
- TVGN 193.1M
- IPO Year
- GNFT 2019
- TVGN N/A
- Fundamental
- Price
- GNFT $3.79
- TVGN $1.24
- Analyst Decision
- GNFT Strong Buy
- TVGN Strong Buy
- Analyst Count
- GNFT 1
- TVGN 1
- Target Price
- GNFT $13.00
- TVGN $10.00
- AVG Volume (30 Days)
- GNFT 4.2K
- TVGN 742.2K
- Earning Date
- GNFT 04-24-2025
- TVGN 08-13-2025
- Dividend Yield
- GNFT N/A
- TVGN N/A
- EPS Growth
- GNFT N/A
- TVGN N/A
- EPS
- GNFT 0.03
- TVGN N/A
- Revenue
- GNFT $73,187,701.00
- TVGN N/A
- Revenue This Year
- GNFT $15.98
- TVGN N/A
- Revenue Next Year
- GNFT N/A
- TVGN N/A
- P/E Ratio
- GNFT $122.19
- TVGN N/A
- Revenue Growth
- GNFT 105.01
- TVGN N/A
- 52 Week Low
- GNFT $2.55
- TVGN $0.26
- 52 Week High
- GNFT $6.42
- TVGN $3.09
- Technical
- Relative Strength Index (RSI)
- GNFT 45.74
- TVGN 49.77
- Support Level
- GNFT $3.61
- TVGN $1.14
- Resistance Level
- GNFT $3.95
- TVGN $1.28
- Average True Range (ATR)
- GNFT 0.15
- TVGN 0.06
- MACD
- GNFT -0.04
- TVGN -0.01
- Stochastic Oscillator
- GNFT 38.80
- TVGN 34.88
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
About TVGN Tevogen Bio Holdings Inc. Common Stock
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.